CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 235 enrolled
Drug / intervention
botulinum toxin Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01603602
NCT01603602Phase 3Completed

BOTOX® Treatment in Pediatric Upper Limb Spasticity: Double-blind Study

Allergan·interventional·Posted May 22, 2012·Updated Aug 14, 2018

In Brief

A Phase 3 clinical trial evaluating botulinum toxin Type A and Normal Saline (Placebo) for Pediatrics and 3 related conditions. Completed, enrolled 235 participants across 45 sites in 9 countries.

Detailed Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Hungary, Philippines, Poland, Russia, South Korea, Thailand, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 22, 2012
Enrollment StartJul 12, 2012
Primary CompletionJun 29, 2017
Study CompletionJul 6, 2017
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 14.1 years ago

Interventions

botulinum toxin Type Abiological

Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.

Normal Saline (Placebo)drug

Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.